arrow
E

Elad Jacoby

h lee moffitt cancer center and research institute
H指数:31
被引数:5,246

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recovery of a CMV-Reactive TCR from a Clinical Virus-Specific T-Cell Product for Generation of a Defined TCR-T Cell Product

从临床病毒特异性T细胞产品中回收CMV反应性TCR以生成定义的TCR-T细胞产品

2026-10-240
OAAI
Plasticity under pressure: biology and detection of lineage switch in acute leukemia

压力下的可塑性:急性白血细胞系的生物学及转换检测

Leukemia
IF13.4
2026-06-260
PRE
Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous hematopoietic stem cell transplantation: a case series

抗CD19 CAR-T细胞疗法作为自体造血干细胞移植后系统性硬化症复发的挽救治疗:一项病例系列研究

2026-04-040
PRE
A Nationwide Analysis of the Phenotype/Genotype Landscape of Hemophagocytic Lymphohistiocytosis: UNC13D Associates with Poor Prognosis

全国范围内对噬血细胞性淋巴组织细胞增生症表型/基因型景观的分析:UNC13D与不良预后相关

2025-11-020
OAAI
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma
2024-06-203
OAAI
INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia

启发研讨会第1部分: 与嵌合抗原受体T细胞治疗b细胞急性淋巴细胞白血病的儿童和年轻人预后改善相关的临床变量

2023-10-016
OAAI
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure

嵌合抗原受体T细胞作为嵌合抗原受体后T细胞衰竭的挽救疗法

2023-09-014
OAAI
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma

大b细胞淋巴瘤中嵌合抗原受体T细胞治疗后的异基因造血细胞移植

2023-02-0116
PRE
Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromes
2022-12-2121
PRE
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
LEUKEMIA
IF13.4
2022-11-0536
OA
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

复发或难治性急性淋巴细胞白血病患儿接受inotuzumab ozogamicin治疗后嵌合抗原受体T细胞治疗的结果

LEUKEMIA
IF13.4
2022-10-309
PRE